- Home
- PWM vs NERV Comparison
PWM vs NERV Comparison
Compare PWM & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PWM
- NERV
- Stock Information
- Founded
- PWM 2018
- NERV 2007
- Country
- PWM Hong Kong
- NERV United States
- Employees
- PWM N/A
- NERV N/A
- Industry
- PWM
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- PWM
- NERV Health Care
- Exchange
- PWM Nasdaq
- NERV Nasdaq
- Market Cap
- PWM 12.4M
- NERV 12.0M
- IPO Year
- PWM 2023
- NERV 2014
- Fundamental
- Price
- PWM $0.40
- NERV $2.00
- Analyst Decision
- PWM
- NERV Hold
- Analyst Count
- PWM 0
- NERV 1
- Target Price
- PWM N/A
- NERV $5.00
- AVG Volume (30 Days)
- PWM 6.3M
- NERV 16.8K
- Earning Date
- PWM 07-29-2025
- NERV 08-05-2025
- Dividend Yield
- PWM N/A
- NERV N/A
- EPS Growth
- PWM N/A
- NERV N/A
- EPS
- PWM N/A
- NERV 0.83
- Revenue
- PWM $639,912.00
- NERV N/A
- Revenue This Year
- PWM N/A
- NERV N/A
- Revenue Next Year
- PWM N/A
- NERV N/A
- P/E Ratio
- PWM N/A
- NERV $2.35
- Revenue Growth
- PWM 83.60
- NERV N/A
- 52 Week Low
- PWM $0.31
- NERV $1.15
- 52 Week High
- PWM $2.70
- NERV $3.35
- Technical
- Relative Strength Index (RSI)
- PWM 50.05
- NERV 62.13
- Support Level
- PWM $0.38
- NERV $1.94
- Resistance Level
- PWM $0.43
- NERV $2.32
- Average True Range (ATR)
- PWM 0.04
- NERV 0.14
- MACD
- PWM -0.00
- NERV 0.03
- Stochastic Oscillator
- PWM 42.17
- NERV 56.55
About PWM Prestige Wealth Inc.
Prestige Wealth Inc is engaged in providing private wealth management services and asset management to high-net-worth and ultra-high-net-worth individuals and enterprises through its subsidiaries.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.